• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肥胖症治疗原则:更新后的S3指南有哪些变化?]

[Principles of obesity treatment: What has changed in the updated S3 guideline?].

作者信息

Rohmann Nathalie, Hollstein Tim, Laudes Matthias

机构信息

Institut für Diabetologie und klinische Stoffwechselforschung, Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel, Düsternbrooker Weg 17, 24105, Kiel, Deutschland.

Abteilung für Endokrinologie, Diabetologie und klinische Ernährungsmedizin, Klinik für Innere Medizin 1, Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Deutschland.

出版信息

Inn Med (Heidelb). 2025 May;66(5):453-460. doi: 10.1007/s00108-025-01900-w. Epub 2025 Apr 8.

DOI:10.1007/s00108-025-01900-w
PMID:40198359
Abstract

A comprehensive update of the S3 guideline for the prevention and treatment of obesity was published in October 2024. In contrast to the former version, the literature search included not only data on weight reduction but also data on patient-reported outcomes and co-morbidity. The new recommendations for nutritional therapy, besides fat and carbohydrate reduction, now also include novel aspects like the Mediterranean diet and intermittent fasting. These will enable individualization and will avoid an unbalanced diet. Pharmacotherapy, especially incretin-based, is recommended in an adjuvant setting, especially since current clinical trials indicate beneficial effects on the heart, liver and kidney in addition to weight reduction. A novel chapter was included regarding eHealth strategies, since these are efficient as supportive measures for multidimensional treatment programs, including nutritional advice, behavioural coaching and exercise training. Finally, a novel aspect was incorporated: discrimination and stigmatization of subjects suffering from obesity. This is important not only for the general environment but also for the medical sector, including the handling of patients as well as the infrastructure of the medical institution (e.g. heavy-duty chairs). Hence, the novel guideline will guarantee high quality in the medical care of subjects suffering from obesity.

摘要

2024年10月发布了关于肥胖症防治的S3指南的全面更新版。与前一版本相比,文献检索不仅包括减重数据,还包括患者报告结局和合并症的数据。营养治疗的新建议,除了减少脂肪和碳水化合物摄入外,现在还包括地中海饮食和间歇性禁食等新内容。这些将实现个体化,并避免不均衡饮食。药物治疗,尤其是基于肠促胰岛素的药物治疗,在辅助治疗中被推荐,特别是因为目前的临床试验表明,除了减重外,对心脏、肝脏和肾脏也有有益作用。新增了关于电子健康策略的章节,因为这些策略作为多维治疗方案的支持措施很有效,包括营养建议、行为指导和运动训练。最后,纳入了一个新内容:对肥胖症患者的歧视和污名化。这不仅对一般环境很重要,对医疗部门也很重要,包括患者的治疗以及医疗机构的基础设施(如重型椅子)。因此,新指南将保证肥胖症患者医疗护理的高质量。

相似文献

1
[Principles of obesity treatment: What has changed in the updated S3 guideline?].[肥胖症治疗原则:更新后的S3指南有哪些变化?]
Inn Med (Heidelb). 2025 May;66(5):453-460. doi: 10.1007/s00108-025-01900-w. Epub 2025 Apr 8.
2
Interventions for promoting habitual exercise in people living with and beyond cancer.促进癌症患者及康复者进行习惯性锻炼的干预措施。
Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity.移动健康(m-health)智能手机干预措施用于超重或肥胖的青少年和成年人。
Cochrane Database Syst Rev. 2024 Feb 20;2(2):CD013591. doi: 10.1002/14651858.CD013591.pub2.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.肥胖治疗的长期效果、经济后果及其对健康改善影响的系统评价
Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210.
7
Physical activity, diet and other behavioural interventions for improving cognition and school achievement in children and adolescents with obesity or overweight.身体活动、饮食及其他行为干预措施对改善肥胖或超重儿童及青少年认知和学业成绩的作用
Cochrane Database Syst Rev. 2018 Mar 2;3(3):CD009728. doi: 10.1002/14651858.CD009728.pub4.
8
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.医疗专业人员在急症医院环境中团队合作教育的经验:对定性文献的系统综述
JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843.
9
Physical activity, diet and other behavioural interventions for improving cognition and school achievement in children and adolescents with obesity or overweight.身体活动、饮食及其他行为干预对改善肥胖或超重儿童及青少年认知和学业成绩的作用
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD009728. doi: 10.1002/14651858.CD009728.pub3.
10
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新:美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新:专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.

本文引用的文献

1
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.替尔泊肽用于射血分数保留的心力衰竭合并肥胖症
N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
2
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.替尔泊肽治疗代谢相关脂肪性肝炎伴肝纤维化
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.
3
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
6
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.超重或肥胖成年人中司美格鲁肽的 2 年疗效:STEP 5 试验。
Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.
7
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
8
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
9
Successful weight loss maintenance: A systematic review of weight control registries.成功的体重维持:体重控制登记的系统回顾。
Obes Rev. 2020 May;21(5):e13003. doi: 10.1111/obr.13003. Epub 2020 Feb 12.
10
Clinical encounters about obesity: Systematic review of patients' perspectives.关于肥胖症的临床问诊:对患者观点的系统综述
Clin Obes. 2020 Feb;10(1):e12347. doi: 10.1111/cob.12347. Epub 2019 Dec 2.